In this study, triple-negative breast cancer (hormone receptor negative, HER2 negative) was selected as the subtype because, although triple-negative breast cancer is a minor subtype among all breast cancer cohorts, it is more common in younger breast cancer (Colleoni et al., 2002; Futamura and Yoshida, 2022). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.